Table III.

Univariate predictions of survival.

	PFS			OS
Category	Median (months)	95% CI	P-value	Median (months)	95% CI	P-value
Total	5.0	3.3–6.7		16.0	8.7–23.3
Age (years)
<65	4.1	2.0–6.2	0.982	15.1	10.5–19.7	0.843
≥65	5.6	2.8–8.4		22.0	5.5-38-5
Gender
Male	4.1	2.7–5.6	0.985	15.1	9.3–20.9	0.902
Female	6.0	2.5–9.50		18.1	5.7–30.6
Histologic type
Adenocarcinoma	5.6	3.3–7.8	0.942	18.1	0.0–36.3	0.716
Non-adenocarcinoma	4.1	1.2–7.0		16.0	8.3–23.7
Performance status
0–1	6.1	3.2–9.0	0.016	29.6	19.9–39.4	<0.001
2	3.0	1.0–5.0		6.1	1.7–10.6
Smoking history
None	5.0	2.8–7.2	0.331	16.0	7.0–25.0	0.780
Current + former	4.9	3.1–6.7		14.1	1.7–26.5
No. of prior regimens
0–1	8.1	3.2–13.0	0.176	29.6	3.3–55.3	0.447
≥ 2	4.0	2.0–6.0		15.0	9.1–20.9
TKI
Gefitinib	5.6	3.6–7.5	0.679	16.0	8.9–23.1	0.935
Erlotinib	3.9	1.5–6.3		24.0	13.2–34.9
Serum CEA level (ng/ml)
<5	4.0	1.7–6.3	0.021	14.0	2.2–25.8	0.505
≥5	7.0	2.5–11.5		18.0	10.3–25.7
Serum CYFRA 21-1 level (ng/ml)
<3.3	8.1	2.9–13.3	0.006	NR		<0.001
≥3.3	3.0	2.0–4.0		8.0	5.2–10.8
Combination of CEA and CYFRA 21-1 (ng/ml)
CEA ≥5 and CYFRA 21-1 <3.3	15.0	5.7–24.3	<0.001	NR		0.002
CEA <5 and CYFRA 21-1 <3.3 or	4.0	3.1–4.9		14.1	5.0–23.2
CEA ≥5 and CYFRA 21-1 ≥3.3
CEA <5 and CYFRA 21-1 >3.3	2.0	0.9–3.1		8.0	4.8–11.2
EGFR mutation (n=84)
Negative	2.0	1.4–2.7	<0.001	7.1	3.9–10.3	0.038
Positive	11.0	5.3–16.7		22.0	13.1–31.0

PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; NR, not reached; EGFR, epidermal growth factor receptor.